Reviewer's report
Title:Efficacy, Safety and Cost Analyses in Ulcerative Colitis Patients
Undergoing Granulocyte and Monocyte Adsorption or Receiving Prednisolone
Version: 2Date:17 January 2013
Reviewer: Takafumi Dr Tabuchi
Reviewer's report:
In this article, the authors report on the analyses of efficacy, safety and cost of
treatment for patients with intractable ulcerative colitis who were treated with a
conventional corticosteroid vs therapeutic granulocyte and monocyte adsorption
(GMA) which is an extracorporeal intervention. The efficacy and safety of GMA
therapy has been reported, with GMA having a very favourable safety profile vs a
glucocorticosteroid. However, the strength of the study on the clinical efficacy vs
economic burden is not very strong. However, it is an important and new point of
view that the authors have focused on the analyses of medical-economic
pertained to the treatment of patients with ulcerative colitis. From this viewpoint,
the manuscript should find interest in clinical settings.
Some references do not numbered in square brackets.
Level of interest: An article of outstanding merit and interest in its field
Quality of written English: Needs some language corrections before being
published
Statistical review: No, the manuscript does not need to be seen by a
statistician.
Declaration of competing interests:
I have no competing interests'
Reviewer's report
Title:Efficacy, Safety and Cost Analyses in Ulcerative Colitis Patients
Undergoing Granulocyte and Monocyte Adsorption or Receiving Prednisolone
Version: 2Date:17 January 2013
Reviewer: Takafumi Dr Tabuchi
Reviewer's report:
In this article, the authors report on the analyses of efficacy, safety and cost of
treatment for patients with intractable ulcerative colitis who were treated with a
conventional corticosteroid vs therapeutic granulocyte and monocyte adsorption
(GMA) which is an extracorporeal intervention. The efficacy and safety of GMA
therapy has been reported, with GMA having a very favourable safety profile vs a
glucocorticosteroid. However, the strength of the study on the clinical efficacy vs
economic burden is not very strong. However, it is an important and new point of
view that the authors have focused on the analyses of medical-economic
pertained to the treatment of patients with ulcerative colitis. From this viewpoint,
the manuscript should find interest in clinical settings.
Some references do not numbered in square brackets.
Level of interest: An article of outstanding merit and interest in its field
Quality of written English: Needs some language corrections before being
published
Statistical review: No, the manuscript does not need to be seen by a
statistician.
Declaration of competing interests:
I have no competing interests'
Please review this paper.
user
Reviewer's report
Title:Efficacy, Safety and Cost Analyses in Ulcerative Colitis Patients
Undergoing Granulocyte and Monocyte Adsorption or Receiving Prednisolone
Version: 2Date:17 January 2013
Reviewer: Takafumi Dr Tabuchi
Reviewer's report:
In this article, the authors report on the analyses of efficacy, safety and cost of
treatment for patients with intractable ulcerative colitis who were treated with a
conventional corticosteroid vs therapeutic granulocyte and monocyte adsorption
(GMA) which is an extracorporeal intervention. The efficacy and safety of GMA
therapy has been reported, with GMA having a very favourable safety profile vs a
glucocorticosteroid. However, the strength of the study on the clinical efficacy vs
economic burden is not very strong. However, it is an important and new point of
view that the authors have focused on the analyses of medical-economic
pertained to the treatment of patients with ulcerative colitis. From this viewpoint,
the manuscript should find interest in clinical settings.
Some references do not numbered in square brackets.
Level of interest: An article of outstanding merit and interest in its field
Quality of written English: Needs some language corrections before being
published
Statistical review: No, the manuscript does not need to be seen by a
statistician.
Declaration of competing interests:
I have no competing interests'
assistant